McGill University Health Centre/Research Institute of the McGill University Health Centre
muhc.caLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
410
Active
99
Phase 3
39
Total enrollment
105,649
Pipeline matrix
Showing 40 of 47 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| acetaminophen | — | — | — | — | 2 | ||
| B/F/TAF | — | — | — | — | — | 1 | |
| Dabigatran | — | — | — | — | — | 1 | |
| Apixaban | — | — | — | — | — | 1 | |
| edoxaban | — | — | — | — | — | 1 | |
| Rivaroxaban | — | — | — | — | — | 1 | |
| Clindamycin + primaquine | — | — | — | — | — | 1 | |
| Pentamidine | — | — | — | — | — | 1 | |
| Atovaquone | — | — | — | — | — | 1 | |
| Systemic corticosteroids | — | — | — | — | — | 1 | |
| Ustekinumab 90 mg SC q8w | — | — | — | — | — | 1 | |
| Ustekinumab 90 mg SC q12w | — | — | — | — | — | 1 | |
| Empagliflozin | — | — | — | — | — | 1 | |
| Normal saline | — | — | — | 4 | |||
| Dexamethasone | — | — | — | — | 2 | ||
| Rifampin double dose | — | — | — | — | 2 | ||
| Vancomycin | — | — | — | — | — | 2 | |
| Tirzepatide | — | — | — | — | — | 1 | |
| Fidaxomicin | — | — | — | — | — | 1 | |
| Semaglutide with 4 meal strategies | — | — | — | — | — | 1 | |
| Intervention Period 1: Semaglutide + Empagliflozin | — | — | — | — | — | 1 | |
| Intervention Period 2: Semaglutide + Empagliflozin Placebo | — | — | — | — | — | 1 | |
| Intervention Period 3: Semaglutide Placebo + Empagliflozin | — | — | — | — | — | 1 | |
| Intervention Period 4: Semaglutide Placebo + Empagliflozin Placebo | — | — | — | — | — | 1 | |
| Oral Vancomycin Prophylaxis | — | — | — | — | — | 1 | |
| rifampin standard arm | — | — | — | — | — | 1 | |
| levofloxacin and rifapentine | — | — | — | — | — | 1 | |
| FLOT | — | — | — | — | — | 1 | |
| Simvastatin | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Canagliflozin 300Mg Tab | — | — | — | — | — | 1 | |
| Inactivated influenza vaccine (IIV) at baseline | — | — | — | — | — | 1 | |
| COVID-19 Vaccines at a 3-month interval | — | — | — | — | — | 1 | |
| Inactivated influenza vaccine at Month 1 | — | — | — | — | — | 1 | |
| COVID-19 Vaccines at a 6-month interval | — | — | — | — | — | 1 | |
| Canagliflozin 300 MG | — | — | — | — | — | 1 | |
| Eligard | — | — | — | — | — | 1 | |
| Metformin | — | — | — | 3 | |||
| Sildenafil Citrate | — | — | — | — | — | 1 | |
| Standard dose rifampicin | — | — | — | — | — | 1 |
7 more active programs hidden
Next readouts
- 2021-10-20
- 2021-12-31
- 2025-05
- 2026-06-01
- 2026-07
- 2026-10-31
- 2026-12-15
- 2027-01
- 2027-01
- 2027-03-31
Top conditions
- HIV Infections7
- COPD7
- Type 1 Diabetes7
- HIV6
- Parkinson's Disease6
- Diabetes Mellitus, Type 16
- Coronary Artery Disease5
- Postoperative Pain5
Frequently asked questions about McGill University Health Centre/Research Institute of the McGill University Health Centre
- How many clinical trials does McGill University Health Centre/Research Institute of the McGill University Health Centre have on ClinicalTrials.gov?
- McGill University Health Centre/Research Institute of the McGill University Health Centre is listed as the lead sponsor on 410 clinical trials in ClinicalTrials.gov, 99 of which are currently active (recruiting, enrolling, or ongoing).
- How many of McGill University Health Centre/Research Institute of the McGill University Health Centre's trials are in Phase 3?
- 39 of McGill University Health Centre/Research Institute of the McGill University Health Centre's trials are in Phase 3, spread across 47 active drug programs.
- What therapeutic areas does McGill University Health Centre/Research Institute of the McGill University Health Centre focus on?
- McGill University Health Centre/Research Institute of the McGill University Health Centre's most-studied conditions on ClinicalTrials.gov are HIV Infections, COPD, Type 1 Diabetes, HIV, Parkinson's Disease.
- When are McGill University Health Centre/Research Institute of the McGill University Health Centre's next clinical trial readouts?
- McGill University Health Centre/Research Institute of the McGill University Health Centre has 10 upcoming primary-completion readouts tracked here; the soonest is “Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM”, expected around 2021-10-20.